

**A novel cell-based assay with  $\alpha 3$  nicotinic receptor detects antibodies selectively in autoimmune autonomic ganglionopathy**

by Karagiorgou et al.,

**Supplementary Tables**

**eTable 1. Search for the optimum conditions for  $\alpha 3\beta 4$ -nAChR CBA**

	CBA with HEK293 cells transfected with $\alpha 3\beta 4$ -nAChR, RIC3 and:			
Patient (numbers as in Table 1)	-	NACHO	Nicotine in the culture	NACHO (+ Nicotine in the culture)
Healthy control	Negative	Negative	Negative	Negative
5	3+	3+	3+	3+
9	1+	3+	1+	3+
10	Negative	1+	1+	2+
12	Negative	2+	1+	2+
18	Negative	Negative	Negative	1+
<b>Total:</b>	<b>4+</b>	<b>9+</b>	<b>6+</b>	<b>11+</b>

1+: weakly positive , 3+: strongly positive. Sera were tested at dilution 1/100, except of serum 18

which was tested at dilution 1/10.

**eTable 2. Clinical information of the AAG-suspected patients, positive for  $\alpha$ 3-nAChR antibodies**

Patient no.	Country	F/M	$\alpha$ 3-nAChR Abs	Final diagnosis	Age at onset	Months with autonomic dysautonomia symptoms up to enrollment	AUTONOMIC MANIFESTATION							EXTRA-AUTONOMIC MANIFESTATIONS			
							Orthostatic hypotension without heart rate changes	Severe constipation	Bladder retention	Loss of sweating	Lightheadedness	Dry mouth and/or dry eyes	Any specific CNS findings	Any specific PNS findings	Presence of any specific cancers?	Other autoimmune diseases?	
1	IT	F	RIA+/CBA+	AAG	67	180	Yes	yes	yes	yes	yes	yes	yes	no	no	no	no
2	IT	M	RIA+/CBA+	AAG	56	48	Yes	no	no	no	no	no	yes	no	no	no	No
3	IT	M	RIA+/CBA+	AAG	77	108	Yes	yes	no	no	no	no	yes	no	no	no	yes <sup>a</sup>
4	IT	M	RIA+/CBA+	AAG	65	192	Yes	yes	no	no	yes	yes	yes	no	no	no	no
5	IT	F	RIA+/CBA+	AAG	64	3	Yes	yes	no	yes	yes	yes	yes	no	no	no	no
6	GR	F	RIA+/CBA+	AAG	70	10	Yes	yes	no	no	yes	yes	yes	no	no	no	no
7	IT	F	RIA+/CBA+	AAG	59	180	Yes	yes	yes	no	yes	yes	yes	no	no	no	no
8	GR	F	RIA+/CBA+	AAG	67	48	Yes	yes	no	yes	yes	yes	no	no	no	no	no
9	IT	F	RIA+/CBA+	AAG	71	30	Yes	yes	yes	yes	yes	yes	yes	no	no	no	no
10	IT	M	RIA+/CBA+	AAG	65	18	Yes	yes	yes	yes	yes	yes	yes	no	no	no	no
11	IT	M	RIA+/CBA+	AAG	53	96	Yes	yes	Bladder incontinence	yes	no	yes	yes	no	no	no	Hashimoto
12	IT	F	RIA+/CBA+	AAG	66	156	Yes	yes	no	yes	no	yes	yes	no	no	no	yes <sup>b</sup>
13	GR	M	RIA+/CBA+	AAG	54	2	Yes	yes	yes	yes	yes	yes	yes	no	no	no	no
14	IT	M	RIA+/CBA+	AAG	49	180	Yes	yes	no	no	yes	yes	yes	no	no	no	no
15	IT	M	RIA+/CBA-	POTS	24	18	No	no	no	no	no	yes	no	no	no	no	no

16	GR	F	RIA+/CBA-	POTS	35	48		No	no	no	no	Yes	no		Yes <sup>c</sup>	No	no	no
17	GR	M	RIA+/CBA-	IMG*	47	-		No	yes	no	no	no	no		no	no	no	no
18	IT	M	RIA+/CBA+	AAG <sup>#</sup>	60	12		Yes	no	no	yes	yes	yes		no	no	no	no
19	GR	F	RIA+/CBA-	ASG*	44	12		No	no	no	yes	no	no		no	no	no	Yes <sup>d</sup>

\*IMG: Inflammatory myenteric ganglionopathy; ASG: autoimmune sensory ganglionopathy

<sup>#</sup>Limited symptoms of AAG (with transient episode of hypotension)

<sup>a</sup>Anti-parietal gastric cells. This patient is described in ref. 22.

<sup>b</sup>Autoimmune thyroiditis – Sjogren

<sup>c</sup>Visual positive disturbances in the form of palinopsia, flickering lights and blurred vision - PET showed focal hypometabolism in visual cortex bilaterally and right temporal cortex.

<sup>d</sup>Presence of anti-ANA, SS-A (Ro), and SS-B (La) antibodies

**eTable 3. Immunoglobulin class and subclass of the CBA-positive sera<sup>a</sup>**

Patient no. (as in Table 1)	Ig class, subclass*				
	IgG1	IgG2	IgG3	IgG4	IgM
	CBA for $\alpha 3\beta 4$ nAChR				
1	+	-	-	-	-
2	+	-	-	-	-
3	+	+	+	-	-
4	+	-	-	-	+
5	+	-	-	-	-
6	+	-	-	-	-
7	+	-	-	-	-
8	+	-	+	NT	-
9	+	-	-	-	-
10	+	-	-	-	-
11	+	-	-	-	-
12	+	-	-	-	-
13	+	-	-	-	-
14	+	+	-	-	-

<sup>a</sup> Sera were incubated with  $\alpha 3\beta 4$  nAChR transfected cells at 1/10 dilution. After fixation, cells were incubated with mouse anti-human IgG1, IgG2, IgG3 or IgG4 (Invitrogen) at 1/500 dilution or IgM at 1/200 dilution. Then Alexa Fluor-488 goat anti-mouse IgG at 1/750 dilution was added as 3rd antibody.

\* +: positive, -: negative, NT: not tested